Brigham and Women's Hospital and Dana-Farber/Harvard Cancer Center, Boston, Massachusetts; Harvard Radiation Oncology Program, Massachusetts General Hospital, Boston, Massachusetts.
Brigham and Women's Hospital and Dana-Farber/Harvard Cancer Center, Boston, Massachusetts; Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):142-151. doi: 10.1016/j.ijrobp.2018.09.010. Epub 2018 Sep 15.
Therapeutic radiation has conflicting immune effects: radiation therapy (RT)-induced immunogenic cell death can contribute to immune response, but lymphocytes are also sensitive to RT. It is unknown whether palliative RT leads to lymphopenia in patients treated with immune checkpoint inhibitors (ICIs) and whether this affects outcomes. As such, we sought to assess the impact of palliative RT on circulating lymphocyte count and neutrophil-to-lymphocyte ratio in patients being treated with PD-1-directed ICI and associations with survival.
We identified patients from 5 radiation oncology centers, treated with palliative RT and either pembrolizumab or nivolumab with non-small cell lung cancer, metastatic melanoma, and renal cell carcinoma. Patients who received intervening cytotoxic chemotherapy were excluded. We recorded absolute lymphocyte count (ALC) and neutrophil-to-lymphocyte ratio before and after palliative RT and at the start of ICI. Survival was analyzed using the Kaplan-Meier method and Cox proportional hazard models.
One hundred ten patients received 225 courses of palliative RT. Median change in ALC after RT was -161 cells/mL. Decreases in ALC were greater with RT to the spine, lung/mediastinum, and chest wall compared with the brain, extremity, or abdomen/pelvis (P = .002) and after courses >5 fractions (P = .003). Extracranial and >5-fraction RT was associated with increased odds of severe lymphopenia (ALC <500) at the end of RT (odds ratio [OR], 3.7; P = .001; and OR, 3.9; P = .001, respectively). Patients who developed RT-induced severe lymphopenia were more likely to have severe lymphopenia when ICI was initiated (OR, 6.4; P = .0001), particularly when RT was administered in the previous 3 months (OR, 189; P < .0001). Severe lymphopenia at onset of ICI therapy was associated with increased mortality on multivariable analysis (hazard ratio, 2.1; P = .03).
Extracranial or prolonged courses of RT increase the risk of severe lymphopenia, which is associated with poorer survival in patients treated with ICI.
治疗性辐射具有相互矛盾的免疫效应:辐射诱导的免疫原性细胞死亡有助于免疫反应,但淋巴细胞也对辐射敏感。目前尚不清楚姑息性放疗是否会导致接受免疫检查点抑制剂(ICI)治疗的患者发生淋巴细胞减少症,以及这是否会影响结局。因此,我们试图评估姑息性放疗对接受 PD-1 定向 ICI 治疗的患者循环淋巴细胞计数和中性粒细胞与淋巴细胞比值的影响,并探讨其与生存的关系。
我们从 5 个放射肿瘤学中心中确定了接受姑息性放疗且患有非小细胞肺癌、转移性黑色素瘤和肾细胞癌的患者,并接受了 pembrolizumab 或 nivolumab 治疗。排除了接受中间细胞毒性化疗的患者。我们记录了姑息性放疗前后以及开始 ICI 时的绝对淋巴细胞计数(ALC)和中性粒细胞与淋巴细胞比值。使用 Kaplan-Meier 方法和 Cox 比例风险模型分析生存情况。
110 例患者接受了 225 次姑息性放疗。放疗后 ALC 的中位数变化为-161 个细胞/mL。与脑部、四肢或腹部/骨盆相比,脊柱、肺/纵隔和胸壁的放疗以及>5 个分次的放疗后 ALC 下降更大(P=0.002)(P=0.003)。颅外和>5 个分次的放疗与放疗结束时严重淋巴细胞减少症(ALC<500)的发生几率增加相关(比值比[OR],3.7;P=0.001;OR,3.9;P=0.001)。当 ICI 开始时,发生放疗诱导的严重淋巴细胞减少症的患者更有可能出现严重淋巴细胞减少症(OR,6.4;P=0.0001),特别是在放疗前 3 个月内进行放疗时(OR,189;P<0.0001)。ICI 治疗开始时发生严重淋巴细胞减少症与多变量分析中死亡率增加相关(风险比,2.1;P=0.03)。
颅外或延长的放疗疗程会增加严重淋巴细胞减少症的风险,这与接受 ICI 治疗的患者的生存较差相关。